Structure Therapeutics (GPCR) News Today $32.71 -0.07 (-0.21%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Rating of "Buy" from AnalystsStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has received an average recommendation of "Buy" from the six brokerages that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price targetNovember 20 at 5:26 AM | marketbeat.comLifesci Capital Issues Optimistic Estimate for GPCR EarningsNovember 20 at 2:09 AM | americanbankingnews.comSepterna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 MilestonesNovember 19 at 3:02 PM | benzinga.comFY2024 Earnings Forecast for GPCR Issued By Lifesci CapitalStructure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Stock analysts at Lifesci Capital raised their FY2024 earnings estimates for shares of Structure Therapeutics in a research note issued to investors on Wednesday, November 13th. Lifesci Capital analyst M. Belghiti now expects that the compNovember 18 at 2:08 AM | marketbeat.comMorgan Stanley Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)November 15, 2024 | markets.businessinsider.comStructure Therapeutics (NASDAQ:GPCR) Trading Down 8.9% - Here's What HappenedStructure Therapeutics (NASDAQ:GPCR) Trading Down 8.9% - Time to Sell?November 15, 2024 | marketbeat.comStructure Therapeutics to Participate in the Jefferies London Healthcare ConferenceNovember 15, 2024 | globenewswire.comRA Capital Management, L.P. Expands Stake in Structure Therapeutics Inc.November 15, 2024 | gurufocus.comStructure Therapeutics, Inc.: Promising Advances in Metabolic Treatments Drive Buy RecommendationNovember 15, 2024 | markets.businessinsider.comGSA Capital Partners LLP Makes New $1.34 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)GSA Capital Partners LLP acquired a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 30,464 shares of the company's stock, valuNovember 14, 2024 | marketbeat.comStructure Therapeutics expects cash to fund operations through at least 2027November 14, 2024 | markets.businessinsider.comStructure Therapeutics doses first patients in ACCESS clinical studyNovember 14, 2024 | markets.businessinsider.comStructure Therapeutics Reports Third Quarter 2024 Financial Results and Recent HighlightsNovember 13, 2024 | markets.businessinsider.comStructure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for ObesityNovember 13, 2024 | globenewswire.comabrdn plc Has $9.53 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)abrdn plc grew its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 132.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 217,083 shares of the company's stock after buying an additional 123,7November 3, 2024 | marketbeat.comStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024October 31, 2024 | markets.businessinsider.comStructure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by AnalystsStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has been given a consensus recommendation of "Buy" by the six analysts that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price targetOctober 26, 2024 | marketbeat.comStructure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity PatientsOctober 22, 2024 | seekingalpha.comCan Roche Challenge Lilly and Novo in the Weight Loss Market? (GPCR)One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate.October 22, 2024 | marketbeat.comEvan Seigerman’s Buy Rating Highlights Structure Therapeutics’ Innovative Approach in Obesity Treatment MarketOctober 22, 2024 | markets.businessinsider.comConsumer, labor groups urge FTC to block Catalent sale to Novo Holdings - reportOctober 17, 2024 | seekingalpha.comGriffin Asset Management Inc. Takes $634,000 Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Griffin Asset Management Inc. bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,450 shares of the company's stock, valuedOctober 17, 2024 | marketbeat.comStructure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and DiabetesOctober 16, 2024 | msn.comExchange Traded Concepts LLC Grows Stake in Structure Therapeutics Inc. (NASDAQ:GPCR)Exchange Traded Concepts LLC raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 191.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,101 shares of the company's stock after purchaOctober 16, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Shares Down 2.7% - Here's What HappenedStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 2.7% - Time to Sell?October 11, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Purchases 32,839 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)The Manufacturers Life Insurance Company grew its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 53.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,370 shares of the cOctober 8, 2024 | marketbeat.comBank of Montreal Can Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)Bank of Montreal Can bought a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 27,094 shares of the company's stock, valued at approximatelyOctober 7, 2024 | marketbeat.com35,700 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Renaissance Technologies LLCRenaissance Technologies LLC bought a new position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 35,700 shares of the company's stock, valued at approOctober 5, 2024 | marketbeat.comMarshall Wace LLP Purchases 40,693 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Marshall Wace LLP lifted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 115.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 75,934 shares of the company's stock after aOctober 4, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Trading 5.8% Higher Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 5.8%September 30, 2024 | marketbeat.comPerceptive Advisors LLC Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)Perceptive Advisors LLC acquired a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 34,852 shares of the company's stock, valuSeptember 30, 2024 | marketbeat.comIs Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?September 29, 2024 | msn.com18,803 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Scientech Research LLCScientech Research LLC purchased a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 18,803 shares of the company's stock, valued at approximately $738,000.September 29, 2024 | marketbeat.comDriehaus Capital Management LLC Acquires 86,833 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)Driehaus Capital Management LLC lifted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 3.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,577,136 shares of the company's stock after purchasiSeptember 28, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Stock Quotes, Forecast and News SummarySeptember 27, 2024 | benzinga.comDeerfield Management Company L.P. Series C Cuts Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Deerfield Management Company L.P. Series C lessened its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 18.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 844,407 shares of the company's stock after seSeptember 26, 2024 | marketbeat.comFY2024 EPS Estimates for Structure Therapeutics Inc. (NASDAQ:GPCR) Boosted by Cantor FitzgeraldStructure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Structure Therapeutics in a research note issued on Monday, September 23rd. Cantor Fitzgerald analyst P. Agrawal now expects that the company will post earnSeptember 25, 2024 | marketbeat.comNovo Nordisk's Setback Won't Last: A Game-Changing Drug EmergesSeptember 25, 2024 | msn.comCantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)September 24, 2024 | markets.businessinsider.comMorgan Stanley Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Overweight RecommendationSeptember 24, 2024 | msn.comNovo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges (GPCR)Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?September 24, 2024 | marketbeat.comFirst Light Asset Management LLC Buys 441,534 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)First Light Asset Management LLC raised its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 296.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 590,647 shares of the company's stock after purchasing an additional 441,534 sharSeptember 24, 2024 | marketbeat.comMorgan Stanley Begins Coverage on Structure Therapeutics (NASDAQ:GPCR)Morgan Stanley started coverage on shares of Structure Therapeutics in a research note on Monday. They issued an "overweight" rating and a $118.00 price target on the stock.September 23, 2024 | marketbeat.comViking, Structure, Terns benefiting from disappointing Novo Nordisk weight loss dataSeptember 21, 2024 | msn.comStructure Therapeutics Inc. (NASDAQ:GPCR) Stock Position Raised by American Century Companies Inc.American Century Companies Inc. lifted its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 66.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 434,982 shares of the company's stock after buying an adSeptember 21, 2024 | marketbeat.comSeven Eight Capital LP Takes Position in Structure Therapeutics Inc. (NASDAQ:GPCR)Seven Eight Capital LP acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 34,337 shares of the company's stock, valued at approximaSeptember 20, 2024 | marketbeat.comStructure Therapeutics Inc. (NASDAQ:GPCR) Short Interest UpdateStructure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totalling 10,430,000 shares, a drop of 6.9% from the August 15th total of 11,200,000 shares. Currently, 19.0% of the company's stock are sold short. Based on an average daily volume of 851,000 shares, the days-to-cover ratio is currently 12.3 days.September 18, 2024 | marketbeat.comStructure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.September 17, 2024 | globenewswire.comStructure Therapeutics (NASDAQ:GPCR) Trading Down 5%Structure Therapeutics (NASDAQ:GPCR) Shares Down 5%September 16, 2024 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Earns "Overweight" Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday.September 16, 2024 | marketbeat.com Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. GPCR Media Mentions By Week GPCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GPCR News Sentiment▼0.410.46▲Average Medical News Sentiment GPCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GPCR Articles This Week▼134▲GPCR Articles Average Week Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Jazz Pharmaceuticals News Legend Biotech News Madrigal Pharmaceuticals News Elanco Animal Health News Cytokinetics News Blueprint Medicines News Nuvalent News Viking Therapeutics News Corcept Therapeutics News Ionis Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GPCR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
